Botanix Pharmaceuticals 将来の成長

Future 基準チェック /66

Botanix Pharmaceuticals利益と収益がそれぞれ年間99.4%と77.6%増加すると予測されています。EPS は年間増加すると予想されています。自己資本利益率は 3 年後に54.4% 102.1%なると予測されています。

主要情報

99.4%

収益成長率

102.1%

EPS成長率

Pharmaceuticals 収益成長	47.8%
収益成長率	77.6%
将来の株主資本利益率	54.4%
アナリストカバレッジ	Low
最終更新日	11 Sep 2024

今後の成長に関する最新情報

更新なし

Recent updates

業績と収益の成長予測

CHIA:BOT - アナリストの将来予測と過去の財務データ ( )AUD Millions
日付	収益	収益	フリー・キャッシュフロー	営業活動によるキャッシュ	平均アナリスト数
6/30/2027	201	110	100	95	1
6/30/2026	105	34	20	18	1
6/30/2025	36	4	-7	-7	1
6/30/2024	2	-14	-26	-8	N/A
3/31/2024	1	-12	-26	-9	N/A
12/31/2023	0	-10	-27	-10	N/A
9/30/2023	2	-10	-23	-11	N/A
6/30/2023	4	-9	-19	-12	N/A
3/31/2023	5	-10	-20	-12	N/A
12/31/2022	6	-11	-20	-12	N/A
9/30/2022	5	-12	-17	-12	N/A
6/30/2022	3	-13	-14	-11	N/A
3/31/2022	1	-12	-8	-7	N/A
12/31/2021	0	-11	-2	-2	N/A
9/30/2021	3	-7	-3	-3	N/A
6/30/2021	7	-3	-3	-3	N/A
3/31/2021	7	-6	-6	-6	N/A
12/31/2020	7	-9	-8	-8	N/A
9/30/2020	7	-13	-13	-13	N/A
6/30/2020	8	-17	-17	-17	N/A
3/31/2020	8	-18	-21	-21	N/A
12/31/2019	8	-20	-24	-24	N/A
9/30/2019	6	-18	-19	-19	N/A
6/30/2019	5	-17	-13	-13	N/A
3/31/2019	5	-15	-12	-12	N/A
12/31/2018	5	-13	-10	-10	N/A
9/30/2018	3	-12	-10	-10	N/A
6/30/2018	2	-11	-10	-10	N/A
3/31/2018	2	-8	N/A	-8	N/A
12/31/2017	2	-6	N/A	-7	N/A
9/30/2017	1	-5	N/A	-6	N/A
6/30/2017	N/A	-5	N/A	-5	N/A
12/31/2016	N/A	-3	N/A	N/A	N/A

アナリストによる今後の成長予測

収入対貯蓄率: BOTは今後 3 年間で収益性が向上すると予測されており、これは貯蓄率 ( 2.6% ) よりも高い成長率であると考えられます。

収益対市場: BOT今後 3 年間で収益性が向上すると予想されており、これは市場平均を上回る成長と考えられます。

高成長収益: BOT今後 3 年以内に収益を上げることが予想されます。

収益対市場: BOTの収益 ( 77.6% ) Australian市場 ( 5.7% ) よりも速いペースで成長すると予測されています。

高い収益成長: BOTの収益 ( 77.6% ) 20%よりも速いペースで成長すると予測されています。

一株当たり利益成長率予想

将来の株主資本利益率

将来のROE: BOTの自己資本利益率は、3年後には非常に高くなると予測されています ( 54.4 %)。

Botanix Pharmaceuticals 将来の成長

Future 基準チェック /66

主要情報

今後の成長に関する最新情報

Recent updates

Botanix Pharmaceuticals Limited Announces Management Appointments

Botanix Pharmaceuticals Limited, Annual General Meeting, Nov 04, 2024

Full year 2024 earnings released: AU$0.009 loss per share (vs AU$0.008 loss in FY 2023)

Botanix Pharmaceuticals Limited has completed a Follow-on Equity Offering in the amount of AUD 70 million.

New major risk - Financial position

New minor risk - Financial position

Botanix Pharmaceuticals Limited, Annual General Meeting, Mar 01, 2024

Botanix Pharmaceuticals Limited has filed a Follow-on Equity Offering in the amount of AUD 13.5 million.

Botanix Pharmaceuticals Limited has filed a Follow-on Equity Offering in the amount of AUD 13.5 million.

Full year 2023 earnings released: AU$0.008 loss per share (vs AU$0.014 loss in FY 2022)

Botanix Pharmaceuticals Limited, Annual General Meeting, Nov 08, 2023

New minor risk - Financial data availability

Botanix Pharmaceuticals Limited Appoints Howie Mckibbon as Chief Executive Officer

Botanix Pharmaceuticals Limited, Annual General Meeting, Sep 18, 2023

Botanix Pharmaceuticals Limited Announces Confirmation Sofpironium Bromide Nda Formally Under Review

Less than half of directors are independent

Botanix Pharmaceuticals Limited Promotes Howie Mckibbon to Chief Operating Officer

Botanix Pharmaceuticals Limited Announces Positive Data from its BTX 1702 Phase 1B/2 Papulopustular Rosacea Clinical Study

Botanix Pharmaceuticals Limited Submits FDA New Drug Application for Sofpironium Bromide

Botanix Pharmaceuticals Limited, Annual General Meeting, Nov 03, 2022

Full year 2022 earnings released: AU$0.013 loss per share (vs AU$0.003 loss in FY 2021)

Less than half of directors are independent

Botanix Pharmaceuticals Limited Appoints Howie Mckibbon as Chief Commercial Officer and Patricia Walker as Chief Medical Adviser

First half 2022 earnings: EPS in line with analyst expectations despite revenue beat

Botanix Pharmaceuticals Limited Announces Launch of Canine Atopic Dermatitis Program

Full year 2021 earnings released: AU$0.003 loss per share (vs AU$0.018 loss in FY 2020)

Botanix Pharmaceuticals Limited Announces Results from BTX 1204A Pilot Study

First half 2021 earnings released: EPS AU$0.001 (vs AU$0.008 loss in 1H 2020)

Botanix Pharmaceuticals Limited Expands Management Team

Botanix Pharmaceuticals Limited Announces Positive Top-Line Data from BTX 1801 Phase 2A Nasal Decolonisation Proof of Concept Study

Botanix Pharmaceuticals Limited Publishes Antimicrobial Data in Peer-Reviewed Research Journal

Botanix Pharmaceuticals Limited Provides Update on BTX 1801 Phase 2A Clinical Study

Botanix Pharmaceuticals Limited(ASX:BOT) dropped from S&P/ASX Emerging Companies Index

Full year earnings released - AU$0.018 loss per share

業績と収益の成長予測

アナリストによる今後の成長予測

一株当たり利益成長率予想

将来の株主資本利益率

成長企業の発掘